Medicine Information

Bextra Withdrawal Could Be Just the Beginning for Pfizer


The pharmaceutical industry is a tremendously profitable one, as anyone who reads the business pages of their newspaper can see. Although it can take years to develop a new drug and bring it to market, the profits obtained from a breakthrough drug can be staggering. Last year Merck sold about $2.5 billion worth of Vioxx, and Pfizer sold about $1.3 billion worth of Bextra. The profits are huge, but so are the losses if a problem should develop with a pharmaceutical product. Pfizer voluntarily withdrew the popular anti-inflammatory drug Bextra from the market last month, and their stock has suffered from both the loss of sales and the potential for a large number of product liability lawsuits. Pfizer may have to endure a double whammy this year as the FDA announced that they are investigating reports that the impotence drug Viagra may be linked to cases of blindness in male users. Cialis and Levitra were also mentioned in the report, although most of the cases involved the use of Viagra.

The FDA reports shouldn't cause alarm; the agency says that it is investigating fewer than 50 incidents of blindness in patients who use a drug that has been used by more than twenty million people since its introduction seven years ago. The FDA investigation says less about the likelihood of blindness in patients than it does about the agency's own concerns about its reputation. The FDA rightly insists upon rigorous testing of drugs before they reach the market in the name of public safety. But that coin has two sides, and there are those who say that the agency is too quick to approve potentially dangerous drugs and others who say that the agency's testing isn't thorough enough. Adding fuel to the fire are the recent memos obtained from Merck employees that suggest that the company was aggressively marketing Vioxx even though their sales staff knew the drug was potentially dangerous.

There may be no link between Viagra and blindness at all, as the form of sudden blindness alleged to have been caused by Viagra use is common to the sorts of patients who have erectile disfunction. The FDA is just being cautious, as they should be. Further tests will determine if there is an actual link. The party likely to suffer immediately is Pfizer, as stockholders, already concerned about Bextra lawsuits, drove the stock price lower immediately upon the release of the Viagra news. Sales will probably decrease, too, as patients who are now accustomed to reading about drugs being withdrawn from the market may shy away from the product until further tests are done. That could present a huge income for Pfizer, as they currently sell about $2 billion worth of Viagra each year. The drug business is a profitable one, but like any business, comes with risks. This year, it would seem that Pfizer is getting a double dose of bad medicine.

©Copyright 2005 by Retro Marketing. Charles Essmeier is the owner of Retro Marketing, a firm devoted to informational Websites, including Bextra-Info.net, a site devoted to the withdrawn drug Bextra and StructuredSettlementHelp.com, a site devoted to structured settlements.


MORE RESOURCES:

Fange added to SIU’s School of Medicine
Hannibal.net, MO - 16 hours ago
Dr. Timothy James Von Fange has joined the faculty at Southern Illinois University School of Medicine in Quincy as an assistant professor of family and ...
Blessing offering EEGs Hannibal.net
all 2 news articles


Readers want no part of two-tier medicine
Toronto Star,  Canada - 12 hours ago
Dr. Robert Ouellet advances the idea that Canada can develop a European-style health-care system with a public-private blend. This fallacy is promoted by ...
Computerized Reminder System Drove Up Colon Cancer Screening Rates Medical News Today (press release)
all 3 news articles


Ex-NJ politician headed to trial on fraud charges
The Associated Press - 2 hours ago
Wayne R. Bryant is also accused of steering state money to one of his employers, the University of Medicine and Dentistry of New Jersey. ...


Bostwick Therapeutics Announces Initiation of Novel Phase I/II ...
MarketWatch - Sep 5, 2008
... of each patient's own immature dendritic cells obtained from blood-borne precursors and introduced back to the individual ("personalized medicine"). ...


Prof. Mark Kelley '79 Receives New Appointment at IU School of ...
DePauw University, IN - Sep 5, 2008
... of DePauw University, has been appointed Betty and Earl Herr Professor of Pediatric Oncology Research at the Indiana University School of Medicine. ...


Regenerative Medicine International (RMI) Signs AdiStem ...
PR-USA.net (press release), Bulgaria - 16 hours ago
AdiStem, a leading provider of autologous, adipose-derived adult stem cell products and procedures has appointed Regenerative Medicine International to ...


Amarillo Medicine Man On The Move
KFDA, TX - 19 hours ago
Slow moving insurance, Medicare and online pharmacies are just a few of the reasons Amarillo's medicine man closed his doors on Friday. ...


LMHP announces six new staff members
The Newark Advocate, OH - 10 hours ago
Klima earned his medical degree at Wright State University School of Medicine, Dayton. He completed a pediatric residency at Children's Hospital in Columbus ...


CBS News

Pollution risk report was flawed, panel says
Detroit Free Press, United States - 14 hours ago
The CDC asked the Institute of Medicine, an independent board, to review the 2007 report. On Friday, an 11-member institute committee said the report was ...
Review panel criticizes Great Lakes health study WTTE
Review panel criticizes Great Lakes health study WREX-TV
Great Lakes pollution can't be tied to health woes, review finds Detroit Free Press
all 341 news articles


A merry heart is good medicine
The Southern, IL - 13 hours ago
Do you ever feel like your get-up-and-go has already got up and went? This thought came to mind when I read an article a reader sent me a while back. ...

Medicine - Google News

home | site map | Dr. Thad Thomas
© 2006